Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 5/2011

01-05-2011 | Original Paper

Prognostic role of systemic inflammatory response in renal cell carcinoma: a systematic review and meta-analysis

Authors: Ying Wu, Xiaonan Fu, Xiaoli Zhu, Xuelian He, Chao Zou, Yijie Han, Mingchu Xu, Chengjin Huang, Xin Lu, Yulan Zhao

Published in: Journal of Cancer Research and Clinical Oncology | Issue 5/2011

Login to get access

Abstract

Purpose

To summarize the global predicting role of systemic inflammatory response for survival in renal cell carcinoma.

Methods

Eligible studies were identified and assessed for quality through multiple search strategies. Data were collected from studies comparing overall, cancer-specific or relapse-free survival in patients with elevated C-reactive protein (CRP), platelet count (PC) and erythrocyte sedimentation rate (ESR) levels with those with lower levels. Studies were pooled, and combined hazard ratios (HRs) of CRP, PC and ESR for survival were calculated, respectively.

Results

A total of 47 studies were included for meta-analysis (18 for CRP, 15 for PC and 14 for ESR). For overall survival, the pooled HR of CRP (3.23, 95% CI: 1.77, 5.89) was higher than that of PC (1.96, 95% CI: 1.40, 2.75) and that of ESR (1.86, 95% CI: 1.34, 2.59). These indicators were strong predictors for cancer-specific survival with individual HRs being 3.46 (95% CI, 2.80, 4.27) of CRP, 3.22 (95% CI, 2.25, 4.62) of PC, and 3.85 (95% CI, 3.31, 4.48) of ESR, respectively. All three inflammatory indictors also predicted relapse-free survival (HRs > 2.0).

Conclusion

The systemic inflammatory response predicted poor survival in patients with renal cell carcinoma.
Literature
go back to reference Aggarwal BB, Gehlot P (2009) Inflammation and cancer: how friendly is the relationship for cancer patients? Curr Opin Pharmacol 9(4):351–369PubMedCrossRef Aggarwal BB, Gehlot P (2009) Inflammation and cancer: how friendly is the relationship for cancer patients? Curr Opin Pharmacol 9(4):351–369PubMedCrossRef
go back to reference Atzpodien J, Royston P, Wandert T, Reitz M, Grp DT (2003) Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 88(3):348–353PubMedCrossRef Atzpodien J, Royston P, Wandert T, Reitz M, Grp DT (2003) Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 88(3):348–353PubMedCrossRef
go back to reference Bensalah K, Leray E, Fergelot P, Rioux-Leclercq N, Tostain J, Guille F, Patard JJ (2006) Prognostic value of thrombocytosis in renal cell carcinoma. J Urol 175(3):859–863PubMedCrossRef Bensalah K, Leray E, Fergelot P, Rioux-Leclercq N, Tostain J, Guille F, Patard JJ (2006) Prognostic value of thrombocytosis in renal cell carcinoma. J Urol 175(3):859–863PubMedCrossRef
go back to reference Brookman-Amissah S, Kendel F, Spivak I, Pflanz S, Roigas J, Klotz T, May M (2009) Impact of clinical variables on predicting disease-free survival of patients with surgically resected renal cell carcinoma. Bju International 103(10):1375–1380PubMedCrossRef Brookman-Amissah S, Kendel F, Spivak I, Pflanz S, Roigas J, Klotz T, May M (2009) Impact of clinical variables on predicting disease-free survival of patients with surgically resected renal cell carcinoma. Bju International 103(10):1375–1380PubMedCrossRef
go back to reference Casamassima A, Picciariello M, Quaranta M, Berardino R, Ranieri C, Paradiso A, Lorusso V, Guida M (2005) C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol 173(1):52–55PubMedCrossRef Casamassima A, Picciariello M, Quaranta M, Berardino R, Ranieri C, Paradiso A, Lorusso V, Guida M (2005) C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol 173(1):52–55PubMedCrossRef
go back to reference Cho KS, Choi YD, Kim SJ, Il Kim C, Chung BH, Seong DH, Lee DH, Cho JS, Cho IR, Hong SJ (2008) A comprehensive prognostic stratification for patients with metastatic renal clear cell carcinoma. Yonsei Med J 49(3):451–458PubMedCrossRef Cho KS, Choi YD, Kim SJ, Il Kim C, Chung BH, Seong DH, Lee DH, Cho JS, Cho IR, Hong SJ (2008) A comprehensive prognostic stratification for patients with metastatic renal clear cell carcinoma. Yonsei Med J 49(3):451–458PubMedCrossRef
go back to reference Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. Br Med J 315(7109):629–634 Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. Br Med J 315(7109):629–634
go back to reference Erdemir F, Kilciler M, Bedir S, Ozgok Y, Coban H, Erten K (2007) Clinical significance of platelet count in patients with renal cell carcinoma. Urol Int 79(2):111–116PubMedCrossRef Erdemir F, Kilciler M, Bedir S, Ozgok Y, Coban H, Erten K (2007) Clinical significance of platelet count in patients with renal cell carcinoma. Urol Int 79(2):111–116PubMedCrossRef
go back to reference Fossa SD, Kramar A, Droz JP (1994) Prognostic factors and survival in patients with metastatic renal-cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer 30A(9):1310–1314PubMedCrossRef Fossa SD, Kramar A, Droz JP (1994) Prognostic factors and survival in patients with metastatic renal-cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer 30A(9):1310–1314PubMedCrossRef
go back to reference Gogus C, Baltaci S, Filiz E, Elhan A, Beduk Y (2004) Significance of thrombocytosis for determining prognosis in patients with localized renal cell carcinoma. Urology 63(3):447–450PubMedCrossRef Gogus C, Baltaci S, Filiz E, Elhan A, Beduk Y (2004) Significance of thrombocytosis for determining prognosis in patients with localized renal cell carcinoma. Urology 63(3):447–450PubMedCrossRef
go back to reference Hayes DF, Isaacs C, Stearns V (2001) Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia 6(4):375–392PubMedCrossRef Hayes DF, Isaacs C, Stearns V (2001) Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia 6(4):375–392PubMedCrossRef
go back to reference Iimura Y, Saito K, Fujii Y, Kumagai J, Kawakami S, Komai Y, Yonese J, Fukui I, Kihara K (2009) Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J Urol 181(3):1004–1012PubMedCrossRef Iimura Y, Saito K, Fujii Y, Kumagai J, Kawakami S, Komai Y, Yonese J, Fukui I, Kihara K (2009) Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J Urol 181(3):1004–1012PubMedCrossRef
go back to reference Ito K, Asano T, Yoshii H, Satoh A, Sumitomo M, Hayakawa M (2006) Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol 13(11):1365–1370PubMedCrossRef Ito K, Asano T, Yoshii H, Satoh A, Sumitomo M, Hayakawa M (2006) Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol 13(11):1365–1370PubMedCrossRef
go back to reference Jacobsen J, Grankvist K, Rasmuson T, Ljungberg B (2002) Prognostic importance of serum vascular endothelial growth factor in relation to platelet and leukocyte counts in human renal cell carcinoma. Eur J Cancer Prev 11(3):245–252PubMedCrossRef Jacobsen J, Grankvist K, Rasmuson T, Ljungberg B (2002) Prognostic importance of serum vascular endothelial growth factor in relation to platelet and leukocyte counts in human renal cell carcinoma. Eur J Cancer Prev 11(3):245–252PubMedCrossRef
go back to reference Janzen NK, Kim HL, Figlin RA, Belldegrun AS (2003) Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 30(4):843–852PubMedCrossRef Janzen NK, Kim HL, Figlin RA, Belldegrun AS (2003) Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 30(4):843–852PubMedCrossRef
go back to reference Kallakury BVS, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS (2001) Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 7(10):3113–3119PubMed Kallakury BVS, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS (2001) Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 7(10):3113–3119PubMed
go back to reference Karakiewicz PI, Hutterer GC, Trinh QD, Jeldres C, Perrotte P, Gallina A, Tostain J, Patard JJ (2007) C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality—a European study of 313 patients. Cancer 110(6):1241–1247PubMedCrossRef Karakiewicz PI, Hutterer GC, Trinh QD, Jeldres C, Perrotte P, Gallina A, Tostain J, Patard JJ (2007) C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality—a European study of 313 patients. Cancer 110(6):1241–1247PubMedCrossRef
go back to reference Kawai Y, Matsuyama H, Korenaga Y, Misumi T, Eguchi S, Hara T, Nagao K, Ohmi C, Sakano S, Naito K (2009) Preoperative erythrocyte sedimentation rate is an independent prognostic factor in japanese patients with localized clear cell renal cell carcinoma. Urol Int 83(3):306–310PubMedCrossRef Kawai Y, Matsuyama H, Korenaga Y, Misumi T, Eguchi S, Hara T, Nagao K, Ohmi C, Sakano S, Naito K (2009) Preoperative erythrocyte sedimentation rate is an independent prognostic factor in japanese patients with localized clear cell renal cell carcinoma. Urol Int 83(3):306–310PubMedCrossRef
go back to reference Kawata N, Nagane Y, Yamaguchi K, Ichinose T, Hirakata H, Takahashi S (2008) How do symptoms have an impact on the prognosis of renal cell carcinoma? Int J Urol 15(4):299–303PubMedCrossRef Kawata N, Nagane Y, Yamaguchi K, Ichinose T, Hirakata H, Takahashi S (2008) How do symptoms have an impact on the prognosis of renal cell carcinoma? Int J Urol 15(4):299–303PubMedCrossRef
go back to reference Komai Y, Saito K, Sakai K, Morimoto S (2007) Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int 99(1):77–80PubMedCrossRef Komai Y, Saito K, Sakai K, Morimoto S (2007) Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int 99(1):77–80PubMedCrossRef
go back to reference Lee SE, Byun SS, Han JH, Han BK, Hong SK (2006) Prognostic significance of common preoperative laboratory variables in clear cell renal cell carcinoma. BJU Int 98(6):1228–1232PubMedCrossRef Lee SE, Byun SS, Han JH, Han BK, Hong SK (2006) Prognostic significance of common preoperative laboratory variables in clear cell renal cell carcinoma. BJU Int 98(6):1228–1232PubMedCrossRef
go back to reference Lehmann J, Retz M, Nurnberg N, Schnockel U, Raffenberg U, Krams M, Kellner U, Siemer S, Weichert-Jacobsen K, Stockle M (2004) The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma. Cancer 101(7):1552–1562PubMedCrossRef Lehmann J, Retz M, Nurnberg N, Schnockel U, Raffenberg U, Krams M, Kellner U, Siemer S, Weichert-Jacobsen K, Stockle M (2004) The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma. Cancer 101(7):1552–1562PubMedCrossRef
go back to reference Ljungberg B, Grankvist K, Rasmuson T (1997) Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. Eur J Cancer 33(11):1794–1798PubMedCrossRef Ljungberg B, Grankvist K, Rasmuson T (1997) Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. Eur J Cancer 33(11):1794–1798PubMedCrossRef
go back to reference Magera JS, Leibovich BC, Lohse CM, Sengupta S, Cheville JD, Kwon ED, Blute ML (2008) Association of abnormal preoperative laboratory values with survival after radical nephrectomy for clinically confined clear cell renal cell carcinoma. Urology 71(2):278–282PubMedCrossRef Magera JS, Leibovich BC, Lohse CM, Sengupta S, Cheville JD, Kwon ED, Blute ML (2008) Association of abnormal preoperative laboratory values with survival after radical nephrectomy for clinically confined clear cell renal cell carcinoma. Urology 71(2):278–282PubMedCrossRef
go back to reference Masuda H, Kurita Y, Suzuki A, Kanbayashi T, Suzuki K, Fujita K (1997) Prognostic factors for renal cell carcinoma: a multivariate analysis of 320 cases. Int J Urol 4(3):247–253PubMedCrossRef Masuda H, Kurita Y, Suzuki A, Kanbayashi T, Suzuki K, Fujita K (1997) Prognostic factors for renal cell carcinoma: a multivariate analysis of 320 cases. Int J Urol 4(3):247–253PubMedCrossRef
go back to reference Masuda H, Kurita Y, Fukuta K, Mugiya S, Suzuki K, Fujita K (1998) Significant prognostic factors for 5-year survival after curative resection of renal cell carcinoma. Int J Urol 5(5):418–422PubMedCrossRef Masuda H, Kurita Y, Fukuta K, Mugiya S, Suzuki K, Fujita K (1998) Significant prognostic factors for 5-year survival after curative resection of renal cell carcinoma. Int J Urol 5(5):418–422PubMedCrossRef
go back to reference Miyake H, Sakai I, Muramaki M, Kurahashi T, Takenaka A, Fujisawa M (2009) Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens. Int J Urol 16(5):465–471PubMedCrossRef Miyake H, Sakai I, Muramaki M, Kurahashi T, Takenaka A, Fujisawa M (2009) Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens. Int J Urol 16(5):465–471PubMedCrossRef
go back to reference Miyata Y, Koga S, Nishikido M, Noguchi M, Kanda S, Hayashi T, Saito Y, Kanetake H (2001) Predictive values of acute phase reactants, basic fetoprotein, and immunosuppressive acidic protein for staging and survival in renal cell carcinoma. Urology 58(2):161–164PubMedCrossRef Miyata Y, Koga S, Nishikido M, Noguchi M, Kanda S, Hayashi T, Saito Y, Kanetake H (2001) Predictive values of acute phase reactants, basic fetoprotein, and immunosuppressive acidic protein for staging and survival in renal cell carcinoma. Urology 58(2):161–164PubMedCrossRef
go back to reference O’Keefe SC, Marshall FF, Issa MM, Harmon MP, Petros JA (2002) Thrombocytosis is associated with a significant increase in the cancer specific death rate after radical nephrectomy. J Urol 168(4):1378–1380PubMedCrossRef O’Keefe SC, Marshall FF, Issa MM, Harmon MP, Petros JA (2002) Thrombocytosis is associated with a significant increase in the cancer specific death rate after radical nephrectomy. J Urol 168(4):1378–1380PubMedCrossRef
go back to reference Paret C, Schon Z, Szponar A, Kovacs G (2010) Inflammatory protein serum amyloid A1 marks a subset of conventional renal cell carcinomas with fatal outcome. Eur Urol 57(5):859–866PubMedCrossRef Paret C, Schon Z, Szponar A, Kovacs G (2010) Inflammatory protein serum amyloid A1 marks a subset of conventional renal cell carcinomas with fatal outcome. Eur Urol 57(5):859–866PubMedCrossRef
go back to reference Parmar MKB, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17(24):2815–2834PubMedCrossRef Parmar MKB, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17(24):2815–2834PubMedCrossRef
go back to reference Peccatori J, Barkholt L, Demirer T, Sormani MP, Bruzzi P, Ciceri F, Zambelli A, Da Prada GA, Pedrazzoli P, Siena S, Massenkeil G, Martino R, Lenhoff S, Corradini P, Rosti G, Ringden O, Bregni M, Niederwieser D, European Bone Marrow T (2005) Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. Cancer 104(10):2099–2103PubMedCrossRef Peccatori J, Barkholt L, Demirer T, Sormani MP, Bruzzi P, Ciceri F, Zambelli A, Da Prada GA, Pedrazzoli P, Siena S, Massenkeil G, Martino R, Lenhoff S, Corradini P, Rosti G, Ringden O, Bregni M, Niederwieser D, European Bone Marrow T (2005) Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. Cancer 104(10):2099–2103PubMedCrossRef
go back to reference Pflanz S, Brookman-Amissah S, Roigas J, Kendel F, Hoschke B, May M (2008) Impact of macroscopic tumour necrosis to predict survival of patients with surgically resected renal cell carcinoma. Scand J Urol Nephrol 42(6):507–513PubMedCrossRef Pflanz S, Brookman-Amissah S, Roigas J, Kendel F, Hoschke B, May M (2008) Impact of macroscopic tumour necrosis to predict survival of patients with surgically resected renal cell carcinoma. Scand J Urol Nephrol 42(6):507–513PubMedCrossRef
go back to reference Ramankulov A, Lein M, Johannsen M, Schrader M, Miller K, Loening SA, Jung K (2008) Serum amyloid a as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma. Cancer Lett 269(1):85–92PubMedCrossRef Ramankulov A, Lein M, Johannsen M, Schrader M, Miller K, Loening SA, Jung K (2008) Serum amyloid a as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma. Cancer Lett 269(1):85–92PubMedCrossRef
go back to reference Ramsey S, Lamb GWA, Aitchison M, Graham J, McMillan DG (2007) Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer 109(2):205–212PubMedCrossRef Ramsey S, Lamb GWA, Aitchison M, Graham J, McMillan DG (2007) Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer 109(2):205–212PubMedCrossRef
go back to reference Ramsey S, Lamb GWA, Aitchison M, McMillan DC (2008) Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer. Bju International 101(8):959–963PubMedCrossRef Ramsey S, Lamb GWA, Aitchison M, McMillan DC (2008) Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer. Bju International 101(8):959–963PubMedCrossRef
go back to reference Roosen JU, Engel U, Jensen RH, Kvist E, Schou G (1994) Renal-cell carcinoma—prognostic factors. Br J Urol 74(2):160–164PubMedCrossRef Roosen JU, Engel U, Jensen RH, Kvist E, Schou G (1994) Renal-cell carcinoma—prognostic factors. Br J Urol 74(2):160–164PubMedCrossRef
go back to reference Roxburgh CSD, McMillan DC (2010) Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncology 6(1):149–163PubMedCrossRef Roxburgh CSD, McMillan DC (2010) Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncology 6(1):149–163PubMedCrossRef
go back to reference Royston P, Sauerbrei W, Ritchie A (2004) Is treatment with interferon-alpha effective in all patients with metastatic renal carcinoma? A new approach to the investigation of interactions. Br J Cancer 90(4):794–799PubMedCrossRef Royston P, Sauerbrei W, Ritchie A (2004) Is treatment with interferon-alpha effective in all patients with metastatic renal carcinoma? A new approach to the investigation of interactions. Br J Cancer 90(4):794–799PubMedCrossRef
go back to reference Sengupta S, Lohse CM, Cheville JC, Leibovieh BC, Thompson RH, Webster WS, Frank I, Zincke H, Blute ML, Kwon ED (2006) The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma. Cancer 106(2):304–312PubMedCrossRef Sengupta S, Lohse CM, Cheville JC, Leibovieh BC, Thompson RH, Webster WS, Frank I, Zincke H, Blute ML, Kwon ED (2006) The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma. Cancer 106(2):304–312PubMedCrossRef
go back to reference Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama 283(15):2008–2012PubMedCrossRef Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama 283(15):2008–2012PubMedCrossRef
go back to reference Suppiah R, Shaheen PE, Elson P, Misbah SA, Wood L, Motzer RJ, Negrier S, Andresen SW, Bukowski RM (2006) Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer 107(8):1793–1800PubMedCrossRef Suppiah R, Shaheen PE, Elson P, Misbah SA, Wood L, Motzer RJ, Negrier S, Andresen SW, Bukowski RM (2006) Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer 107(8):1793–1800PubMedCrossRef
go back to reference Symbas NP, Townsend MF, El-Galley R, Keane TE, Graham SD, Petros JA (2000) Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int 86(3):203–207PubMedCrossRef Symbas NP, Townsend MF, El-Galley R, Keane TE, Graham SD, Petros JA (2000) Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int 86(3):203–207PubMedCrossRef
go back to reference Tanaka M, Fujimoto K, Okajima E, Tanaka N, Yoshida K, Hirao Y (2008) Prognostic factors of renal cell carcinoma with extension into inferior vena cava. Int J Urol 15(5):394–398PubMedCrossRef Tanaka M, Fujimoto K, Okajima E, Tanaka N, Yoshida K, Hirao Y (2008) Prognostic factors of renal cell carcinoma with extension into inferior vena cava. Int J Urol 15(5):394–398PubMedCrossRef
go back to reference Tourani JM, Pfister C, Tubiana N, Ouldkaci M, Prevot G, Lucas V, Oudard S, Malet M, Cottu P, Ferrero JM, Mayeur D, Rixe O, Sun XS, Bernard O, Andre T, Tournigand C, Muracciole X, Guilhot J (2003) Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: Final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design-the subcutaneous administration propeukin program cooperative group. J Clin Oncol 21(21):3987–3994PubMedCrossRef Tourani JM, Pfister C, Tubiana N, Ouldkaci M, Prevot G, Lucas V, Oudard S, Malet M, Cottu P, Ferrero JM, Mayeur D, Rixe O, Sun XS, Bernard O, Andre T, Tournigand C, Muracciole X, Guilhot J (2003) Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: Final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design-the subcutaneous administration propeukin program cooperative group. J Clin Oncol 21(21):3987–3994PubMedCrossRef
go back to reference Vakkila J, Lotze MT (2004) Opinion—Inflammation and necrosis promote tumour growth. Nat Rev Immunol 4(8):641–648PubMedCrossRef Vakkila J, Lotze MT (2004) Opinion—Inflammation and necrosis promote tumour growth. Nat Rev Immunol 4(8):641–648PubMedCrossRef
go back to reference Vogl U, Zehetgruber H, Dominkus M, Hejna M, Zielinski C, Haitel A, Schmidinger M (2006) Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br J Cancer 95(6):691–698PubMedCrossRef Vogl U, Zehetgruber H, Dominkus M, Hejna M, Zielinski C, Haitel A, Schmidinger M (2006) Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br J Cancer 95(6):691–698PubMedCrossRef
go back to reference Zubac DP, Bostad L, Seidal T, Wentzel-Larsen T, Haukaas SA (2008) The prognostic relevance of interactions between venous invasion, lymph node involvement and distant metastases in renal cell carcinoma after radical nephrectomy. BMC Urol 8:19PubMedCrossRef Zubac DP, Bostad L, Seidal T, Wentzel-Larsen T, Haukaas SA (2008) The prognostic relevance of interactions between venous invasion, lymph node involvement and distant metastases in renal cell carcinoma after radical nephrectomy. BMC Urol 8:19PubMedCrossRef
Metadata
Title
Prognostic role of systemic inflammatory response in renal cell carcinoma: a systematic review and meta-analysis
Authors
Ying Wu
Xiaonan Fu
Xiaoli Zhu
Xuelian He
Chao Zou
Yijie Han
Mingchu Xu
Chengjin Huang
Xin Lu
Yulan Zhao
Publication date
01-05-2011
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 5/2011
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-010-0951-3

Other articles of this Issue 5/2011

Journal of Cancer Research and Clinical Oncology 5/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine